Dr. John Robert Hartono, MD

Dr. Hartono practices at Baylor Ambulatory Endoscopy Center - HOPD in Plano, Texas.

Dr. Hartono's NPI, 1477576965, was assigned on July 25, 2006. Dr. Hartono graduated from University Of Minnesota Medical School in 2004. Dr. Hartono's Texas license number on file is P0223.

Dr. Hartono's primary practice is Baylor Ambulatory Endoscopy Center - HOPD, at 4708 Alliance Blvd, Plano, TX 75093.

Dr. Hartono's primary practice is Baylor Ambulatory Endoscopy Center - HOPD in Plano, Texas. Dr. Hartono is also affiliated with Medical City Plano Hospital. The medical group on file is Advanced Kidney Care. Dmand AI also links Dr. Hartono to 5 more hospitals, 2 dialysis centers, 1 group practice or clinic, 1 hospital outpatient department and 1 ambulatory surgery center, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Hartono practices, 12 sites in all. Vendor and product names are available with a free account.

Nephrology is Dr. Hartono's primary specialty in the NPI Registry, under taxonomy code 207RN0300X. Dr. Hartono is board certified in internal medicine by the American Board of Internal Medicine. Dr. Hartono has a license on file in Texas.

Dmand AI lists acute kidney failure, chronic kidney disease, fluid and electrolyte imbalances and hypercalcemia among the conditions Dr. Hartono treats.

CMS data shows 1,406 Medicare services from Dr. Hartono across 7 procedure codes in 2024, for 470 Medicare patients. Medicare paid $146,710 for them.

CMS counts 470 Medicare patients who saw Dr. Hartono in 2024. The largest group is 75 to 84, with 185 patients. 75% of them have chronic kidney disease, and 75% have high blood pressure. 10% are also on Medicaid. Their average risk score is 3.26, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Hartono's median patient age at 69, with 37% women.

In 2024, Dr. Hartono wrote 2,184 Medicare Part D claims for 361 patients. 87% of them were for generic drugs. CMS names the drug for 1,856 of them, across 46 drugs with 11 or more claims each, at $225,153 in total drug cost. In 2023, CMS named 1,832 claims across 48 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Hartono for performance year 2024, reported as part of a group. Dr. Hartono accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 5 papers to Dr. Hartono, published from 2009 to 2011. The most frequent topics are Acute Kidney Injury, Endothelial Cells and HMGB1 Protein. Dr. Hartono's most frequent co-authors are Christopher Yu-Hua Lu, MD, Pamela Dietz Winterberg, MD and Reji John, MD.

CMS Open Payments shows 38 general payments to Dr. Hartono from 15 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 97% of the total. AstraZeneca Pharmaceuticals LP paid the most, $335.

Dmand AI lists 1 award for Dr. Hartono, most recently CMS Stage 1 EHR in 2013.

Dr. Hartono graduated from University Of Minnesota Medical School in 2004.

Dr. Hartono is in network with 23 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. HMO plans come from the most carriers, 14. Check the plan with the practice before a visit.